Inspirion Wealth Advisors buys $10,225,945 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Inspirion Wealth Advisors scooped up 11,473 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 227,496 shares of Abbott Laboratories which is valued at $10,225,945.Abbott Laboratories makes up approximately 6.46% of Inspirion Wealth Advisors’s portfolio.

Other Hedge Funds, Including , Hutchinson Capital Managementca reduced its stake in ABT by selling 100 shares or 1.74% in the most recent quarter. The Hedge Fund company now holds 5,638 shares of ABT which is valued at $253,428. Abbott Laboratories makes up approx 0.08% of Hutchinson Capital Managementca’s portfolio.Blue Fin Capital reduced its stake in ABT by selling 250 shares or 1.34% in the most recent quarter. The Hedge Fund company now holds 18,435 shares of ABT which is valued at $824,966. Abbott Laboratories makes up approx 0.67% of Blue Fin Capital’s portfolio.Benedict Financial Advisors Inc reduced its stake in ABT by selling 85 shares or 0.12% in the most recent quarter. The Hedge Fund company now holds 70,137 shares of ABT which is valued at $3,062,883. Abbott Laboratories makes up approx 1.77% of Benedict Financial Advisors Inc’s portfolio.New York State Teachers Retirement System reduced its stake in ABT by selling 96,794 shares or 3.36% in the most recent quarter. The Hedge Fund company now holds 2,780,462 shares of ABT which is valued at $120,032,545. Abbott Laboratories makes up approx 0.30% of New York State Teachers Retirement System’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.